On July 16, 2012, the Food and Drug Administration approved the use of Truvada (tenofovir and emtricitabine) for HIV Pre-Exposure Prophylaxis (PrEP) in patients at high risk of HIV infection.
On May 26, 2016, the Delaware Academy of Medicine, in cooperation with the Delaware HIV Consortium and Delaware PrEP, hosted a day long conference about PrEP and its uses. 